Furthermore, we found that decreasing RIPK1 dosing frequency by 50% resulted in a similar tumor inhibition effect when combined with anti-PD1 (Supplementary Fig. 8), suggesting that the safety profile of RIPK1 degraders can be further improved by optimizing the dosing regimen. Here, RIPK1 is linked to neoplasm.